Supernova Bio is a R&D-focused bio-venture that has developed therapeutic agents for lipolysis, anti-lipoma, and liposarcoma by utilizing gas-generating polymer nanoparticles that significantly reduce adipose tissue. Supernova Bio’s adipo-cytolytic agents are nanoparticles manufactured from FDA-approved biocompatible polymers. And The surface of these nanoparticles are covered with peptides targeting adipocytes. These nanoparticles selectively and effectively generate carbon dioxide within adipocytes, causing cell death and reduction of adipose tissue. Currently, Supernova Bio is partnering with a pharmaceutical company with cGMP facilities in order to finalize SOP (standard operating procedure) and CMC (chemistry, manufacturing, control). Supernova Bio’s innovative therapeutic agents represent a significant technological advancement over what is currently available in the body fat reduction market and are poised to disrupt the industry.